Cleared Traditional

K861394 - EMIT DIGOXIN MOBILE PHASE SOLUTION

K861394 is the FDA 510(k) clearance for EMIT DIGOXIN MOBILE PHASE SOLUTION by Syva Co.. It is a Class 2 Chemistry device (product code KXT) cleared through the Traditional 510(k) pathway after a 45-day FDA review.

K861394 · Syva Co. · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
May 1986
Decision
45d
Days
Class 2
Risk

K861394 is an FDA 510(k) clearance for the EMIT DIGOXIN MOBILE PHASE SOLUTION. Classified as Enzyme Immunoassay, Digoxin (product code KXT), Class II - Special Controls.

Submitted by Syva Co. (Palo Alto, US). The FDA issued a Cleared decision on May 29, 1986 after a review of 45 days - a notably fast clearance cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.3320 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Syva Co. devices

Submission Details

510(k) Number K861394 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 14, 1986
Decision Date May 29, 1986
Days to Decision 45 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
43d faster than avg
Panel avg: 88d · This submission: 45d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code KXT Enzyme Immunoassay, Digoxin
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3320
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - KXT Enzyme Immunoassay, Digoxin

All 69
Devices cleared under the same product code (KXT) and FDA review panel - the closest regulatory comparables to K861394.
DIGOXIN FPIA REAGENT SET
K870951 · Sigma Diagnostics, Inc. · Apr 1987
DELFIA DIGOXIN
K861195 · Lkb Instruments, Inc. · Jul 1986
EMIT COLUMN DIGOXIN ASSAY
K861393 · Syva Co. · May 1986
CEDIA DIGOXIN ASSAY
K854638 · Microgenics Corp. · Mar 1986
COBAS FP REAGENTS FOR DIGOXIN & COBAS FP DIGOXIN C
K851032 · Roche Diagnostic Systems, Inc. · Apr 1985
DUPONT DIGOXIN ASSAY REAGENTS
K850458 · E.I. Dupont DE Nemours & Co., Inc. · Mar 1985